Medindia

X

Perceptive Informatics Enhances Musculoskeletal Medical Imaging Capabilities Through Alliance with Optasia

Thursday, September 17, 2009 General News J E 4
Advertisement


BOSTON, Sept. 16 Perceptive Informatics, a leading eClinical solutions provider and a subsidiary of PAREXEL International Corporation (Nasdaq: PRXL), today announced that it has enhanced its capabilities to provide medical imaging measurements for osteoarthritis clinical trials through an alliance with Optasia Medical, Inc. Perceptive Informatics is using Optasia's KneeAnalyzer(TM) software to supplement its existing medical imaging technology to improve the reproducibility of and reduce the time involved with image analysis of the knee in osteoarthritis patients.



"Medical imaging plays an important role in the early evaluation of new compounds in musculoskeletal related clinical research, including in the growing areas of rheumatoid arthritis, osteoporosis, and osteoarthritis," said Kenneth G. Faulkner, Ph.D., Vice President of Medical Imaging, Perceptive Informatics. "Our alliance with Optasia provides customers with better surrogate measurements in trials focused on knee-related osteoarthritis, a progressive disease. This relationship represents our commitment to help customers accelerate trials and speed new treatments to patients in the musculoskeletal therapeutic area."



Optasia develops software, which issued in clinical trials to identify and monitor patients who will benefit from treatment, to facilitate the more rapid, accurate evaluation of medical images with greater reproducibility. Optasia's software applications are based on the Optasia Platform, which employs model-based vision technology to detect, measure, classify and compare two-dimensional medical images.



Perceptive Informatics has a broad range of musculoskeletal imaging clinical research experience and capabilities. The Medical Imaging Group of Perceptive Informatics offers a range of capabilities in the application of imaging techniques from early clinical development through peri-approval studies. The medical imaging team operates globally and services a wide range of therapeutic areas, including oncology, neurology, rheumatology, cardiology, and endocrinology.



About Perceptive Informatics

Perceptive Informatics, a leading eClinical solutions provider and subsidiary of PAREXEL, is focused on helping customers to accelerate the product development process through innovation. The Perceptive Informatics industry-leading eClinical product portfolio is built on advanced technology that benefits from extensive medical and clinical expertise as well as a deep understanding of the regulatory environment. The portfolio includes Randomization and Trial Supply Management (RTSM) technologies, Medical Imaging, Clinical Trial Management Systems (CTMS), Electronic Data Capture (EDC), and Electronic Patient-Reported Outcomes (ePRO). For more information about the integrated solutions in Perceptive's eClinical Suite visit: www.perceptive.com.



About PAREXEL International

PAREXEL International Corporation is a leading global biopharmaceutical services organization, providing a broad range of knowledge-based contract research, medical communications and consulting services to the worldwide pharmaceutical, biotechnology and medical device industries. Committed to providing solutions that expedite time-to-market and peak-market penetration, PAREXEL has developed significant expertise across the development and commercialization continuum, from drug development and regulatory consulting to clinical pharmacology, clinical trials management, medical education and reimbursement. Perceptive Informatics, Inc., a subsidiary of PAREXEL, provides advanced technology solutions, including medical imaging, to facilitate the clinical development process. Headquartered near Boston, Massachusetts, PAREXEL operates in 70 locations throughout 52 countries around the world, and has over 9,275 employees. For more information about PAREXEL International visit www.PAREXEL.com.



This release contains "forward-looking" statements regarding future results and events. For this purpose, any statements contained herein that are not statements of historical fact may be deemed forward-looking statements. Without limiting the foregoing, the words "believes," "anticipates," "plans," "expects," "intends," "appears," "estimates," "projects," "targets," and similar expressions are also intended to identify forward-looking statements. The forward-looking statements in this release involve a number of risks and uncertainties. The Company's actual future results may differ significantly from the results discussed in the forward-looking statements contained in this release. Important factors that might cause such a difference include, but are not limited to, risks associated with: actual operating performance; actual expense savings and other operating improvements resulting from recent restructurings; the loss, modification, or delay of contracts which would, among other things, adversely impact the Company's recognition of revenue included in backlog; the Company's dependence on certain industries and clients; the Company's ability to win new business, manage growth and costs, and attract and retain employees; the Company's ability to complete additional acquisitions and to integrate newly acquired businesses or enter into new lines of business, including, but not limited to, the successful business integration and anticipated synergy achievements in connection with the ClinPhone acquisition; the impact on the Company's business of government regulation of the drug, medical device and biotechnology industry; consolidation within the pharmaceutical industry and competition within the biopharmaceutical services industry; the potential for significant liability to clients and third parties; the potential adverse impact of health care reform; and the effects of exchange rate fluctuations and other international economic, political, and other risks. Such factors and others are discussed more fully in the section entitled "Risk Factors" of the Company's Annual Report on Form 10-K for the year ended June 30, 2009 as filed with the SEC on August 28, 2009, which "Risk Factors" discussion is incorporated by reference in this press release. The forward-looking statements included in this press release represent the Company's estimates as of the date of this release. The Company specifically disclaims any obligation to update these forward-looking statements in the future. These forward-looking statements should not be relied upon as representing the Company's estimates or views as of any date subsequent to the date of this press release.



PAREXEL is a registered trademark of PAREXEL International Corporation, and Perceptive Informatics is a trademark of Perceptive Informatics, Inc. All other names or marks may be registered trademarks or trademarks of PAREXEL International Corporation, Perceptive Informatics, Inc. or their respective owners and are hereby acknowledged.



Contacts: Jennifer Baird, Senior Director Gene Carozza/Kim Baker of Public Relations PAREXEL International PAN Communications Tel: +781-434-4409 Tel: +978-474-1900 Email: Jennifer.Baird@PAREXEL.com Email: PAREXEL@pancomm.com

SOURCE PAREXEL International Corporation
Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
Savient Provides Update on Meeting with U.S. Food ...
S
GENova and TheraGlass in advanced negotiations